Mometason/olopatadine
Generic name
Mometason/olopatadine
Brand name
ATC Code
R01AD59
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
In adults after intranasal administration:
Tmax: 1 hour
T1/2: mometasonfuroate 18-20 hours; olopatadine 6-7 hours
Cmax: 19,80 ± 7,01 ng/ml for olopatadine and 9,92 ± 3,74 pg/ml for mometasonfuroate
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Allergic rhinitis: furoate |
|---|
|
Renal impaiment in children > 3 months
No information available on dose adjustment in renal impairment.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Growth retardation may occur in children and adolescents taking long-term nasal corticosteroids.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
It is recommended that the height of children and adolsecents treated with nasal corticosteroids for prolonged periods be monitored regularly.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Sympathomimetics, plain | ||
|---|---|---|
| R01AA08 | ||
| R01AA05 | ||
| R01AA09 | ||
| R01AA07 | ||
| Sympathomimetics, combinations excl. corticosteroids | ||
|---|---|---|
| R01AB01 | ||
| Antiallergic agents, excl. corticosteroids | ||
|---|---|---|
| R01AC03 | ||
| R01AC01 | ||
| R01AC02 | ||
| Corticosteroids | ||
|---|---|---|
| R01AD58 | ||
| R01AD01 | ||
| R01AD05 | ||
| R01AD08 | ||
| R01AD12 | ||
| R01AD12 | ||
| R01AD09 | ||
| R01AD11 | ||
| Other nasal preparations | ||
|---|---|---|
| R01AX10 | ||
| OTHER NASAL PREPARATIONS | ||
|---|---|---|
| R01AX10 | ||
Reference
- Glenmark Pharmaceuticals s.r.o, SmPC Ryaltris (RVG 126186) 5 december 2024, Geneesmiddeleninformatiebank.nl
Changes
Therapeutic Drug Monitoring
Overdose
